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Summary
Background Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary analysis was to evaluate the prognostic value of PET-CT responses after first-line immunochemotherapy in the GALLIUM study.
Methods
GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1-3a;
disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years or older and met the criteria for needing treatment. Eligible patients were randomly assigned in a 1:1 ratio to receive intravenous administration of obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles) or rituximab (375 mg/m² on day 1 of each cycle), in six 21-day cycles with cyclophosphamide, doxorubicin, vincristine, and prednisone (known as CHOP; oral administration) followed by two 21-day cycles of antibody alone, or eight 21-day cycles cyclophosphamide, vincristine, and prednisone (known as CVP; oral administration), or six 28-day cycles with bendamustine, followed by maintenance antibody every 2 months for up to 2 years. The primary endpoint of the trial, investigator-assessed progression-free survival, has been reported previously. This secondary analysis reports PET and CT-based responses at end-of-induction therapy and explains their relation with progression-free and overall survival outcomes in patients with available scans. As per protocol, during the trial, PET scans (mandatory in the first 170 patients enrolled at sites with available PET facilities, and optional thereafter), acquired at baseline and end of induction (PET population), were assessed prospectively by investigators and an independent review committee (IRC) applying International Harmonisation Project (IHP) 2007 response criteria, and retrospectively by the IRC only applying current Lugano 2014 response criteria.
IRC members (but not study investigators) were masked to treatment and clinical outcome when assessing response. The landmark analyses excluded patients who died or progressed (contrast enhanced CT-based assessment of progressive disease, or started next anti-lymphoma treatment) before or at end of induction. GALLIUM is registered at ClinicalTrials.gov, number NCT01332968. (95% CI 83·7-90·2) and in non-complete metabolic responders was 54·9% (40·5-67·3; HR 0·2, 95% CI 0·1-0·3, p<0·0001).
Interpretation Our results suggest that PET is a better imaging modality than contrastenhanced CT for response assessment after first-line immunochemotherapy in patients with follicular lymphoma. PET assessment according to Lugano 2014 response criteria provides a platform for investigation of response-adapted therapeutic approaches. Additional supportive data are welcomed. doxorubicin, vincristine, and prednisone) without maintenance therapy. There is also some evidence that end of induction PET response could be prognostic for overall survival, although small sample sizes have prevented a robust assessment. In this secondary analysis of the GALLIUM trial, the first randomised study to compare first-line immunochemotherapy with obinutuzumab versus rituximab plus maintenance therapy in patients with follicular lymphoma, we further investigate the potential prognostic role of PET in this setting.
Added value of this study
This secondary analysis from GALLIUM provides prospective PET data from a large population of patients with follicular lymphoma receiving a wide spectrum of modern immunochemotherapies, including bendamustine-based treatment and different anti-CD20 maintenance antibodies. The results of retrospective analysis applying the current, internationally accepted Lugano 2014 response criteria (which incorporates the ordinal 5-point scale [Deauville criteria] for evaluating PET scans) presented here suggests that, for patients with follicular lymphoma, achieving a complete metabolic response is prognostic for improved progression-free and overall survival in this indolent but heterogeneous lymphoma.
These data support the use of end-of-induction PET response status as a practical, early predictor of progression-free and overall survival, helping to identify patients with the greatest risk of relapse.
Implications of all the available evidence
Evidence from this secondary analysis and previous studies suggest PET as a superior imaging modality compared with contrast-enhanced CT for response assessment in patients with follicular lymphoma treated with first-line immunochemotherapy. PET-response assessment at the end of induction therapy could inform patients and their clinicians of the probability of both progression-free and overall survival. The data also support the use of PET assessment according to Lugano 2014 response criteria as a platform to study responseadapted therapeutic approaches in future clinical trials to improve outcomes for patients with follicular lymphoma.
Introduction
Follicular lymphoma is the most common indolent non-Hodgkin lymphoma, and has heterogeneous clinical behaviour. Follicular lymphoma is highly sensitive to initial therapy, but is characterised by recurrent relapses and risk of histological transformation. In the modern era of combined immunochemotherapy, with the promise shown with the type 2
anti-CD20 antibody obinutuzumab in the ongoing GALLIUM trial in this setting, 1 the lengthy remission and overall survival for some patients (possibly beyond 20 years after diagnosis) now challenges the perception of follicular lymphoma as incurable.
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Many patients are more likely to die from other causes while in remission or with asymptomatic disease than from the diagnosed follicular lymphoma itself. Nonetheless, a substantial minority of patients (approximately 20%) have a poor prognosis, and these patients are not reliably identified at diagnosis by conventional response assessment based on CT and bone marrow analyses. 4, 5 There is preliminary evidence from studies suggesting that 2-18 F-fluoro-2-deoxy-D-glucose ( 18 F-FDG) PET-CT response after induction therapy is prognostic for outcomes in follicular lymphoma. Findings from three prospective studies of first-line immunochemotherapy for high-tumour-burden follicular lymphoma showed almost universal 18 F-FDG uptake in follicular lymphoma, and progression-free survival was significantly longer in those patients with a negative PET at end of treatment compared with those with a positive PET. 4, 6, 7 In one study, patients remaining PET positive had a significantly (p=0·001) inferior progression-free survival at 42 months of 32·9% (95% CI 17·2-49·5) compared with 70·7% (59·3-79·4) in those who became PET negative. 4 In another study, with a median follow-up of 23 months, 2-year progression-free survival was 51% for patients who remained PET-positive versus 87% for patients who became PET-negative (p<0·001). 6 In the third study, with a median follow-up of 34 months, the 3-year progression-free survival was 35% and 66%, respectively, for patients with positive and negative postinduction PET (p<0·001).
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A pooled analysis of these studies with longer follow-up was conducted; scans were centrally reviewed by three independent PET physicians. Post-treatment PET with a cutoff score of four or greater (defined as ¹ ⁸ F-FDG uptake in tumour higher than that in the liver) on the 5-point scale (also known as the Deauville criteria) 8, 9 was prognostic (4-year On the basis of the above mentioned findings from several cohort studies suggesting the prognostic value of post-treatment PET in follicular lymphoma, [4] [5] [6] [7] 10 we hypothesised that patients with follicular lymphoma who achieved PET negativity in the GALLIUM trial could have better prognosis in terms of both progression-free and overall survival than PET-positive patients. The aim of the current prespecified secondary analysis was to evaluate the PET response at end of induction with immunotherapy and to explore its prognostic value in patients with follicular lymphoma treated within the GALLIUM study.
Methods

Study design and participants
This is a secondary analysis of PET results from GALLIUM, an ongoing randomised, open-label, parallel-group, phase 3 trial. An early protocol amendment on July 26, 2011
made PET mandatory at baseline and at the end-of-induction therapy for a minimum of 170 patients recruited for the GALLIUM trial at sites where PET scanning was available, becoming optional thereafter. The updated study protocol is available in the appendix (pp 9-235).
The study design and patient population for GALLIUM including full eligibility criteria have been described previously. The study is being done in accordance with the International Conference on
Harmonisation guidelines for Good Clinical Practice, and the protocol was approved by the ethics committee at each participating centre. Patients provided written informed consent before any study-specific procedures were performed.
Randomisation and masking
During GALLIUM, patients were randomly assigned 1:1 to receive intravenous infusions of obinutuzumab or rituximab plus chemotherapy of choice. Randomisation was done by means of an interactive voice-response or online response system with the use of a hierarchical dynamic randomisation scheme and stratified by induction chemotherapy regimen Patients with a CT-based complete response or partial response at end of induction received maintenance treatment with the antibody they received during induction (1000 mg obinutuzumab or 375 mg/m² rituximab) every 2 months for 2 years, or until progressive disease or study withdrawal; no crossover was permitted. Those with stable disease at end of induction were followed on the same schedule as patients receiving maintenance, but were not prescribed antibody maintenance. Disease assessments including CT scans were done every 4 months for the first year and every 6 months for the second year of maintenance. Patients were then followed up every 3 months for 3 years (with CT scans every 6 months), then every 6 months for 2 years (with annual CT scans) until the end of the study or until disease progression. Patients with disease progression were followed up for overall survival every 6 months until the end of the study, and were treated at the discretion of the investigator, according to institutional practice.
PET scans were done at baseline (≤35 days before randomisation) and at end of induction (6-8 weeks after day 1 of the last cycle of chemotherapy) or early study termination. Scans were assessed by investigators and an IRC, comprising two radiologists who were masked to clinical outcome, and a third adjudicating radiologist whose role was to resolve any disagreements between the radiologists relating to the attributed response; the final IRC response was determined by an independent clinician (masked to treatment and outcome) who considered the final radiological response in addition to bone marrow and other biopsy information.
CT and PET response was evaluated for patients achieving a partial response or complete response as per the International Harmonisation Project (IHP) 2007 response criteria. 12, 13 Both investigator and IRC reporting adhered to IHP 2007 response criteria.
According to these criteria, any end-of-induction PET with ¹ ⁸ F-FDG uptake greater than or equal to uptake in the mediastinum in lesions of 2 cm or larger, or uptake greater than that of adjacent background tissue in lesions smaller than 2 cm, was defined as PET positive.
These assessments were prespecified in the GALLIUM study protocol (appendix pp 9-235). PET scans to assess metabolic response were also retrospectively assessed by the IRC only according to the more recent Lugano 2014 response criteria, 8, 11 incorporating the 5-point scale as an exploratory analysis. By these criteria, positive scans were defined by a residual ¹ ⁸ F-FDG uptake score of 4 or greater (ie, uptake greater than the maximum standardised uptake value in a large region of normal liver). In accordance with the Lugano 2014 criteria, recognised causes for ¹ ⁸ F-FDG uptake other than follicular lymphoma were assigned as unrelated to follicular lymphoma. For CT scans, as per IHP 2007 criteria, patients formerly assigned to unconfirmed complete response 14 are generally classified as partial response. Bone marrow biopsy was done in all patients at baseline and was required in patients with conventional CT-based complete response at end of induction.
Outcomes
The primary endpoint of the GALLIUM trial was investigator-assessed progression-free survival (defined as the time from randomisation to the first occurrence of progression or relapse) in patients with follicular lymphoma. Key secondary efficacy endpoints were progression-free survival in all randomised patients, overall survival (defined as the time from the date of randomisation to the date of death from any cause) in all patients with follicular lymphoma and all randomised patients, and the proportion of patients achieving an overall and complete response in all patients with follicular lymphoma and all randomised patients, as previously reported. 1 This secondary analysis, which will report CT and PET-based responses at end-ofinduction therapy and explore their relation with progression-free and overall survival outcomes in patients with available scans, was prespecified as an exploratory analysis of the trial in a protocol amendment on July 26, 2011.
Statistical analysis
The data reported in the primary GALLIUM study report were from a preplanned interim analysis, when the prespecified significance level for the primary endpoint had been crossed (cutoff Jan 31, 2016). 1 The results reported in this Article are from an updated analysis (cutoff Sept 10, 2016).
As a secondary analysis of the GALLIUM trial, the analyses presented in this report are not powered. Demographic and baseline characteristics were summarised using descriptive statistics in the PET population (defined as all randomly assigned patients with available baseline and end-of-induction PET scans; the non-PET population included all other randomly assigned patients).
Response Estimates of the differences between groups were determined using a stratified Cox proportional hazards analysis and expressed as HRs and 95% CIs. Estimated 2·5-year probabilities, including 95% CIs, were also used to describe progression-free and overall survival. Exploratory univariate and multivariable Cox analyses were undertaken to investigate factors that were prognostic for progression-free and overall survival. GALLIUM is registered at ClinicalTrials.gov, number NCT01332968.
Role of the funding source
The funder was involved in trial design, and in data collection, analysis, and interpretation. Authors who were employees of the funder (TN, DS, and GRF-R) contributed to the writing and approval of the manuscript. JZ and DS have full access to the raw data, and all authors had limited access to the data and statistical results. All authors have approved the final draft of the manuscript and the corresponding author had the final responsibility to submit for publication.
Results
Patients were enrolled into GALLIUM between July 6, 2011, and Feb 4, 2014. The trial profile for the primary study population has been published previously. showing that complete metabolic response status and obinutuzumab treatment group were the only significant independent predictors of progression-free survival. Complete metabolic response status was the only significant independent predictor of overall survival.
The safety data for this updated analysis have been reported elsewhere.
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Discussion
This secondary analysis of GALLIUM is, to our know-ledge, the first large study of PET response assessment in follicular lymphoma. The secondary endpoint of PET-based response as assessed with the IHP 2007 response criteria was prognostic in terms of progression-free survival; however, the more recent Lugano 2014 response criteria served as a better tool for prognosis, detecting a five-times increase in risk of progression and early death in patients who did not achieve a complete metabolic remission compared with those who did not achieve a complete metabolic response.
The proportion of patients achieving a complete metabolic response as per PET assessment established with the current, internationally accepted Lugano 2014 criteria, 8, 11 incorporating the 5-point scale, was more than two-times higher than the proportion achieving complete response determined by CT-based assessment by the IHP 2007 criteria. We suggest that this discrepancy between the two imaging modalities might be due to PET imaging more accurately distinguishing between viable lymphoma and non-lymphoma residual lesions than CT. Most patients who qualified for the landmark analysis achieved a complete metabolic response. Notably, there was a significant separation of the progression-free and overall survival curves between patients achieving a complete metabolic response and those who did not. Of considerable importance was the worse overall survival in patients who did not achieve a complete metabolic response. With a five-times increased risk of death in these patients on multivariate analysis, and 16% of this population dying within just 2·5 years of the end of induction (13% due to their lymphoma), this finding suggests PET status as an early predictor of decreased overall survival in this disease.
With better predictive ability than CT-based response assessment, PET status could be used to guide patients in making important life decisions and to assist physicians in determining the frequency of clinical follow-up.
This study has a few limitations. We acknowledge that the Lugano 2014 analysis was performed retrospectively in response to updated international guidelines and that valid per-protocol PET scans were only available in half of the follicular lymphoma population from GALLIUM. We also acknowledge that there was a higher frequency of CT scans during the 2-year maintenance period of the GALLIUM study than would currently be considered standard of care. Another limitation of this study is the effect on management of patients with stable disease, who were not mandated antibody maintenance. However, only four patients in the PET population had stable disease by CT as assessed by investigators, three of whom also received maintenance therapy, which suggests little effect on the results.
When assessing the GALLIUM data in the context of earlier research, we note findings from a previous retrospective pooled analysis 5 of three multicentre studies, However, we note that GALLIUM was not designed to compare differences between the different chemotherapy backbones. 16 Faced with a heterogeneous disease, clinicians treating follicular lymphoma have previously lacked robust and clinically useful early post-induction predictors of survival.
With modern immunochemotherapy, the median progression-free survival after first-line therapy and maintenance is estimated to be approximately 10 years, 17 making progression-free survival per se an increasingly impractical endpoint in clinical trials, which require more than 1000 participants and several years of follow-up to demonstrate incremental advances. There is a growing body of evidence to suggest that quantitative PET measures could be prognostic in follicular lymphoma. 26, 27 Analysis of baseline total metabolic tumour volume, incorporated with pretreatment prognostic indices and metabolic response, might increase separation between the progression-free survival curves of the patients with or without a complete metabolic response, specifically to better identify the 10-15% of patients with complete metabolic response who do progress early. Further PET analyses might also contribute to improved understanding of why some patients without complete metabolic response do not progress early, particularly the obinutuzumab-treated population, for whom we hypothesise that for PET assessment after obinutuzumab-based therapy.
In conclusion, these data suggest that PET is a better assessment modality than contrastenhanced CT in patients with follicular lymphoma treated with first-line immunochemotherapy.
Further studies, combining PET with other prognostic tools, might help to identify patients at high risk of both relapse and early death to optimise risk-adapted follow-up. Although additional validation is required, PET might be a useful, early surrogate marker of progressionfree and overall survival in clinical trials, and provide the platform to guide response-adapted therapy in follicular lymphoma.
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